Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	108649
Country	China

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Fibroblast growth factor 19-fibroblast growth factor receptor 4 axis: From oncogenesis to targeted-immunotherapy in advanced hepatocellular carcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Tian-Ao Zhan, Feng Xia, Hong-Wei Huang, Jun-Cheng Zhan, Xin-Kang Liu and Qi Cheng
Funding Agency and Grant Number	Funding Agency Grant Number Chen Xiao-Ping Foundation for The Development of Science and Technology of Hubei Province CXPJJH124001-2406 National Natural Science Foundation of China U23A20483
Corresponding Author	Qi Cheng, MD, PhD, Professor, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan 430030, Hubei Province, China. chengqi@hust.edu.cn
Key Words	Hepatocellular carcinoma; Fibroblast growth factor 19; Selective fibroblast growth factor receptor 4 inhibitor; Adverse events; Resistance; Targeted-immunotherapy; Tumor microenvironment; Biomarker
Core Tip	The aberrant Fibroblast growth factor 19 (FGF19)-fibroblast growth factor receptor 4 (FGFR4) axis plays a crucial role in progression of hepatocellular carcinoma. Multi-kinase inhibitors enhance anti-tumor effects by targeting the FGF19-FGFR4 axis and FGF19 overexpression contributes to the development of immune suppression. These findings highlight the association between FGF19 and targeted-immunotherapy in hepatocellular carcinoma (HCC). Selective FGFR4 inhibitors, either alone or combining with targeted-immunotherapy, have demonstrated therapeutic potential for advanced HCC, although the clinical application is hindered by challenges such as adverse effects and drug resistance. Furthermore, FGF19 serves as a promising biomarker for HCC, underscoring its potential for precision treatment.
Citation	Zhan TA, Xia F, Huang HW, Zhan JC, Liu XK, Cheng Q. Fibroblast growth factor 19-fibroblast growth factor receptor 4 axis: From oncogenesis to targeted-immunotherapy in advanced hepatocellular carcinoma. World J Gastrointest Oncol 2025; In press

Received	2025-04-21 03:31
Peer-Review Started	2025-04-21 03:31
To Make the First Decision
Return for Revision	2025-05-11 13:08
Revised	2025-05-25 04:09
Second Decision	2025-07-18 02:43
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-07-18 08:51
Articles in Press	2025-07-18 08:51
Publication Fee Transferred	2025-05-26 12:18
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com